InsiderTrades

Form 4 for RVMD Revolution Medicines, Inc.

Accepted 2026-04-17 19:26:28 ET · period of report 2026-04-15 · accession 0001610717-26-000146 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMT 2026-04-17 19:26 2026-04-15 RVMD GOLDSMITH MARK A See Remarks, Dir M - OptEx $4.61 +120.0K 396.7K +43% +$552.7K
DT 2026-04-17 19:26 2026-04-15 RVMD GOLDSMITH MARK A See Remarks, Dir S - Sale+OE $150.09 -120.0K 276.7K -30% -$18.01M
DMT 2026-04-17 19:26 2026-04-15 RVMD GOLDSMITH MARK A See Remarks, Dir M - OptEx $0.00 -120.0K 424.1K -22% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-04-15 M A 23,244 $4.09 299,942 D — — (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. (F2) Includes 201,150 restricted stock units.
2 Common Common Stock 2026-04-15 M A 96,756 $4.73 396,698 D — — (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. (F2) Includes 201,150 restricted stock units.
3 Common Common Stock 2026-04-15 S D 120,000 $150.09 276,698 D — — (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. (F3) This transaction was executed in multiple trades at prices ranging from $150.00 to $150.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. (F2) Includes 201,150 restricted stock units.
4 Derivative Stock Option (Right to Buy) 2026-04-15 M D 23,244 $0.00 24,464 D $4.09 · 2023-03-13 to 2029-03-12 23,244 Common Stock (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024.
5 Derivative Stock Option (Right to Buy) 2026-04-15 M D 96,756 $0.00 424,085 D $4.73 · 2023-08-09 to 2029-08-08 96,756 Common Stock (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024.